Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction

Tavakoli-Ardakani, Maria; Haghighi, Shirin; Shokouhi, Shervin; Abtahi‐Naeini, Bahareh; Meidani, Mohsen; Hassanpour, Rezvan; Saffaei, Ali

doi:10.5152/eurasianjmed.2019.18459

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We developed PBPK models to characterize DDIs between crizotinib and triazole antifungals in patients with cancer, yet there are limitations in our work. There are studies that indicate that crizotinib is a substrate for P‐glycoprotein (P‐gp), and voriconazole and itraconazole are potential inhibitors of P‐gp 44,48,49 . Inhibition of P‐gp may also be involved in the DDIs between crizotinib and voriconazole or itraconazole.…”

Section: Discussionmentioning

confidence: 99%

“…There are studies that indicate that crizotinib is a substrate for P-glycoprotein (P-gp), and voriconazole and itraconazole are potential inhibitors of P-gp. 44,48,49 Inhibition of P-gp may also be involved in the DDIs between crizotinib and voriconazole or itraconazole. In our study, we hypothesized that the P-gp was not involved in the DDIs between crizotinib and triazole antifungal agents in order to reduce the complexity of the PBPK models.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib

Chen

2022

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Crizotinib is used for the treatment of c-ros oncogene 1-positive advanced non-small-cell lung cancer. Triazole antifungal agents are widely used for invasive fungal infections in clinical practice. To predict the potential influence of different triazoles (voriconazole, fluconazole, and itraconazole) on the pharmacokinetics of crizotinib by modeling and simulation the physiologically based pharmacokinetic models were established and validated in virtual cancer subjects through Simcyp software based on the essential physicochemical properties and pharmacokinetic data collected. The validated physiologically based pharmacokinetic models were applied to predict the drug-drug interactions between crizotinib and different triazoles (voriconazole, fluconazole, or itraconazole) in patients with cancer. Crizotinib and triazole antifungal agents were administered orally. The predicted plasma concentration vs time profiles of crizotinib, voriconazole, fluconazole, and itraconazole showed good agreement with observed, respectively. The geometric mean area under the plasma concentration-time curve (AUC) of crizotinib was increased by 84%, 58%, and 79% when coadministered with voriconazole, fluconazole, or itraconazole at multiple doses, respectively. The drug-drug interaction results showed increased pharmacokinetic exposure (maximum plasma concentration and area under the plasma concentration-time curve) of crizotinib when coadministrated with different triazoles (voriconazole > itraconazole > fluconazole). Among the 3 triazoles, voriconazole exhibited the most significant influence on the pharmacokinetic exposure of crizotinib. In clinic, adverse drug reactions and toxicity related to crizotinib should be carefully monitored, and therapeutic drug monitoring for crizotinib is recommended to guide dosing and optimize treatment when coadministered with voriconazole, fluconazole, or itraconazole.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib

Chen

2022

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

Antifungal use in children with acute leukaemia: state of current evidence and directions for future research

Yeoh

Haeusler

McMullan

et al. 2022

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Invasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents. With recent advances in the understanding of IFD epidemiology and large clinical trials in adults assessing antifungals for IFD treatment and prophylaxis, together with paediatric clinical and pharmacokinetic studies, there is a growing body of data to inform optimal antifungal use in children. A panel of infectious diseases and haematology-oncology clinicians with expertise in IFD management compiled a list of 10 key clinical questions following development of the 2021 Australia and New Zealand Mycology Antifungal Consensus Guidelines. A focused literature review was conducted to explore available evidence and identify gaps in knowledge to direct future research. With the changing epidemiology of IFD globally, the ongoing evolution of paediatric leukaemia treatment and the increasing availability of novel antifungal agents, advocacy for paediatric clinical studies will remain vital to optimize IFD prevention and treatment in children with leukaemia.

show abstract

Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction

Abstract: Aims and Scope Eurasian Journal of Medicine (Eurasian J Med) is an international, scientific, open access periodical published by independent, unbiased, and tripleblinded peer-review principles. The journal is the official publication of

Cited by 2 publications

References 13 publications

Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib

Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib

Antifungal use in children with acute leukaemia: state of current evidence and directions for future research

Contact Info

Product

Resources

About